A Phase 1, Open-Label, Randomized, Two-Period Crossover Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets Following Single Oral Doses in Healthy Subjects

The primary purpose of this study is to determine the relative bioavailability of brensocatib between the pediatric oral solution and oral tablets in healthy participants.

开始日期2024-04-30

申办/合作机构

Insmed, Inc.

NCT06178783 / Completed临床1期

A Phase 1, Double-blind, Randomized, Single-center Study to Assess the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Subjects

The primary purpose of this study is to assess the palatability and compare acceptability of brensocatib oral solutions.

开始日期2023-12-27

申办/合作机构

Insmed, Inc.

NCT06013241 / Recruiting临床2期

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps - The BiRCh Study

The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.

开始日期2023-10-30

申办/合作机构

Insmed, Inc.

100 项与 Brensocatib 相关的临床结果

登录后查看更多信息

100 项与 Brensocatib 相关的转化医学

登录后查看更多信息

100 项与 Brensocatib 相关的专利（医药）

登录后查看更多信息

项与 Brensocatib 相关的文献（医药）

2024-07-01·ERJ Open Research

Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics

Article

作者: De Soyza, Anthony ; Mauger, David ; Mange, Kevin ; Fernandez, Carlos ; Conroy, Dan ; Burgel, Pierre-Régis ; Metersky, Mark ; Haworth, Charles S ; Daley, Charles L ; Chalmers, James D ; Teper, Ariel

IntroductionBrensocatib is an investigational, oral, reversible inhibitor of dipeptidyl peptidase-1 shown to prolong time to first exacerbation in adults with bronchiectasis. Outlined here are the clinical trial design, and baseline characteristics and treatment patterns of adult patients enrolled in the phase 3 ASPEN trial (NCT04594369).MethodsThe ASPEN trial is a global study enrolling patients with a clinical history consistent with bronchiectasis (cough, chronic sputum production and/or recurrent respiratory infections), diagnosis confirmed radiologically and ≥2 exacerbations in the prior 12 months. It was designed to evaluate the impact of two brensocatib doses (10 mg and 25 mg) on exacerbation rate over a 52-week treatment periodversusplacebo. Comprehensive clinical data, including demographics, disease severity, lung function,Pseudomonas aeruginosastatus and quality of life, were collected at baseline.Results1682 adults from 35 countries were randomised from December 2020 to March 2023. Mean age was 61.3 years and 64.7% were female. ∼70% had moderate-to-severe Bronchiectasis Severity Index (BSI) scores, 29.3% had ≥3 exacerbations in the prior 12 months and 35.7% were positive forP. aeruginosa. Mean BSI scores were highest in Australia/New Zealand (8.3) and lowest in Latin America (5.9). Overall, the most common aetiology was idiopathic (58.4%). InP. aeruginosa-positiveversus P. aeruginosa-negative patients, lung function was lower, with greater long-term macrolide (21.5%versus14.0%) and inhaled corticosteroid use (63.5%versus53.9%). There was wide regional variation in long-term antibiotic use in patients with bronchiectasis andP. aeruginosa.DiscussionASPEN baseline characteristics and treatment profiles were representative of a global bronchiectasis population.

2024-07-01·Open Respiratory Archives

Bronchiectasis

Review

作者: Erro, Marta ; Sánchez, Carlos ; González, Jessica ; Abril, Rosa ; Suarez-Cuartin, Guillermo ; Pou, Cristina ; Manzano, Carlos ; Zamarrón, Ester ; Raboso, Beatriz

Non-cystic fibrosis bronchiectasis, a condition that remains relatively underrecognized, has garnered increasing research focus in recent years. This scientific interest has catalyzed advancements in diagnostic methodologies, enabling comprehensive clinical and molecular profiling. Such progress facilitates the development of personalized treatment strategies, marking a significant step toward precision medicine for these patients. Bronchiectasis poses significant diagnostic challenges in both clinical settings and research studies. While computed tomography (CT) remains the gold standard for diagnosis, novel alternatives are emerging. These include artificial intelligence-powered algorithms, ultra-low dose chest CT, and magnetic resonance imaging (MRI) techniques, all of which are becoming recognized as feasible diagnostic tools. The precision medicine paradigm calls for refined characterization of bronchiectasis patients by analyzing their inflammatory and molecular profiles. Research into the underlying mechanisms of inflammation and the evaluation of biomarkers such as neutrophil elastase, mucins, and antimicrobial peptides have led to the identification of distinct patient endotypes. These endotypes present variable clinical outcomes, necessitating tailored therapeutic interventions. Among these, eosinophilic bronchiectasis is notable for its prevalence and specific prognostic factors, calling for careful consideration of treatable traits. A deeper understanding of the microbiome's influence on the pathogenesis and progression of bronchiectasis has inspired a holistic approach, which considers the multibiome as an interconnected microbial network rather than treating pathogens as solitary entities. Interactome analysis therefore becomes a vital tool for pinpointing alterations during both stable phases and exacerbations. This array of innovative approaches has revolutionized the personalization of treatments, incorporating therapies such as inhaled mannitol or ARINA-1, brensocatib for anti-inflammatory purposes, and inhaled corticosteroids specifically for patients with eosinophilic bronchiectasis.

2024-07-01·JDR Clinical & Translational Research

Periodontal Effects of the Reversible Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Bronchiectasis

Article

作者: Scannapieco, F A ; Sibila, O ; Fernandez, C ; Chalmers, J D ; Gunsolley, J C

Aims: Brensocatib is a reversible inhibitor of dipeptidyl peptidase 1 (cathepsin C), in development to treat chronic non–cystic fibrosis bronchiectasis. The phase 2, randomized, placebo-controlled WILLOW trial (NCT03218917) was conducted to examine whether brensocatib reduced the incidence of pulmonary exacerbations. Brensocatib prolonged the time to the first exacerbation and led to fewer exacerbations than placebo. Because brensocatib potentially affects oral tissues due to its action on neutrophil-mediated inflammation, we analyzed periodontal outcomes in the trial participants. Materials and Methods: Patients with bronchiectasis were randomized 1:1:1 to receive once-daily oral brensocatib 10 or 25 mg or placebo. Periodontal status was monitored throughout the 24-week trial in a prespecified safety analysis. Periodontal pocket depth (PPD) at screening, week 8, and week 24 was evaluated. Gingival inflammation was evaluated by a combination of assessing bleeding upon probing and monitoring the Löe-Silness Gingival Index on 3 facial surfaces and the mid-lingual surface. Results: At week 24, mean ± SE PPD reductions were similar across treatment groups: −0.07 ± 0.007, −0.06 ± 0.007, and −0.15 ± 0.007 mm with brensocatib 10 mg, brensocatib 25 mg, and placebo, respectively. The distribution of changes in PPD and the number of patients with multiple increased PPD sites were similar across treatment groups at weeks 8 and 24. The frequencies of gingival index values were generally similar across treatment groups at each assessment. An increase in index values 0–1 and a decrease in index values 2–3 over time and at the end of the study were observed in all groups, indicating improved oral health. Conclusions: In patients with non–cystic fibrosis bronchiectasis, brensocatib 10 or 25 mg had an acceptable safety profile after 6 months’ treatment, with no changes in periodontal status noted. Improvement in oral health at end of the study may be due to regular dental care during the trial and independent of brensocatib treatment. Knowledge Transfer Statement: The results of this study suggest that 24 weeks of treatment with brensocatib does not affect periodontal disease progression. This information can be used by clinicians when considering treatment approaches for bronchiectasis and suggests that the use of brensocatib will not be limited by periodontal disease risks. Nevertheless, routine dental/periodontal care should be provided to patients irrespective of brensocatib treatment.

项与 Brensocatib 相关的新闻（医药）

2024-08-29

·佰傲谷BioValley

百济二股东减持Incyte

近日，SEC的13F报告更新了百济二股东Baker Bros Advisor LP在第二季度的持仓明细，百济二股东Baker Brother是知名生物医药领域投资机构，Seagen，百济神州，Incycte等均为其知名投资项目，本文将对此次前十大重仓项目明细进行简单分析。在Baker Brother的重点持仓项目中，与Q1相比，Baker Brother在百济神州，ACADIA Pharmaceuticals，Madrigal Pharmaceuticals，Revolution Medicines，Rhythm Pharmaceuticals等公司的持仓情况基本不变。另外，公司Bicycle Therapeutics最近有重要融资事件发生，Baker Brother应当是看重其作为PDC公司和诺奖转化成果的未来潜力。其他持仓变动幅度较大的则直接有事件相应证。最大重仓Incyte Corporation惨遭减持15% 变动较大的可能是持仓最多的Incyte Corporation，Baker Bro减持了15%。 7月末时暴跌的股价可能应证了这一持仓，在7月末时，Incyte一口气砍掉了5款管线，包括两款口服小分子PD-L1抑制剂INCB99280和INCB99318、一款LAG-3单抗INCAGN2385、一款TIM-3单抗INCAGN2390和一款LAG-3xPD-1双抗INCA32459。总的来说，被砍的原因在于这些项目失去了竞争性。在临床进度上均落后于竞争对手Immutep和BMS，这些竞争对手均开发了PD-1xLAG-3的联合疗法。虽然股价当时受到影响下跌，考虑到这些管线基本上处于早期临床，此次裁撤倒是并未造成太大损失，市场也认为这一举措相对合理。黑马Insmed Incorporated Insmed Incorporated可以说是今年的股价黑马之一，Insmed Incorporated是一家1999年成立的老Biotech，专注的是吸入剂领域，主要开发的是吸入剂的递送技术。虽然成立时间悠久，但最近这家公司展现出了异乎寻常的商业价值，Insmed Incorporated在2016年从阿斯利康处获得了DPP1抑制剂Brensocatib的授权。 8年后，Insmed Incorporated将证明他们买对了Brensocatib。今年5月末时，Insmed Incorporated宣布Brensocatib在治疗非囊性纤维化支气管扩张症（NCFBE）的三期临床ASPEN达到主要临床终点，次要终点也同样达到。非囊性纤维化支气管扩张症是一类严重的慢性疾病，每10万人约有几百人患病，可以说相对较为普遍，患者的症状主要是痰液过多，持续出现呼吸道感染，有时甚至咳血，会显著降低患者的生活质量，但是一直以来治疗方法都是治标不治本，经常是采用抗生素杀菌，或是用支气管舒张剂缓解症状，又或是粘液活性药物来疏通痰液。而DPP1抑制剂Brensocatib代表着这一疾病有了新的特异性方案，DPP1是一种负责激活中性粒细胞丝氨酸蛋白酶的酶，通过抑制DPP1，可以减少中性粒细胞介导的肺损伤和炎症，从而改善病情。这代表着Insmed Incorporated顺利拓宽了该适应症市场，Insmed飙涨的股价很好的反应了这一点。 Baker Bro看重Summit Therapeutics Q213F显示Baker Bro共持有2322千万股Summit Therapeutics 的股票，这也令其一跃成为Baker Bro前十大持仓。 Summit Therapeutics的优秀在于大股东Robert Duggan的眼光和操盘手段。此前该公司以5亿美元预付的高价从康方生物处获得了PD-1/VEGF双抗AK112，总交易额达到了50亿美元。今年5月24日时，ASCO上AK112在非小细胞肺癌上的数据得到了公布，然而这一数据当时被点评为不及预期，被评价是只比化药有优势，市场一片看衰，Summit股价也因此大跌。但5月31日时，剧情反转，AK112头对头战胜K药，Summit股价大涨，一举扫清之前下跌颓势。几天后便传来了Baker Bro以9美元每股的价格认购Summit的2222万股普通股的消息。这或许表明，通过合理操盘最大化股东利益的公司值得Baker Bro投资，同时通过大资本投资稳定市场信心而不至于让股价回落。本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处 · · · · · · · ·

临床3期抗体药物偶联物引进/卖出多肽偶联药物

2024-08-14

·新药前沿

DPP1抑制剂fast-follow者海思科的完美“变现”

First in Class类新药虽是全球生物医药公司的最高追求，但对于国内多数医药公司来说，以目前的实力可能还难以企及。follow策略仍旧是目前国内多数创新药开发者的首选。而在现实中，国内企业仍旧面临着follow（信息、研发等）速度慢、动态评估不科学和关键节点决策不果断等问题（或风险）。【中国follow式创新药系列】将通过一些案例的介绍，希望能够给国内生物医药公司follow First in Class类新药提供经验和思考。 Insmed Incorporated/阿斯利康合作开发的DPP1抑制剂Brensocatib（AZD7986，INS1007）在取4得支气管扩张Ⅲ期临床试验成功之后，公司已经计划于2024年第四季度向美国FDA提交NDA。值得一提的是，阿斯利康最早开发的第一代DPP1抑制剂是AZD5248。AZD5248具有很强的抑制活性和选择性，在大鼠、小鼠和狗模型中的清除率低，生物利用度高。但在大鼠定量全身放射自显影术研究中，AZD5248出现了主动脉结合现象，因此停止了开发。阿斯利康通过优化设计化合物AZD7986不与主动脉组织匀浆结合，并在血浆中表现出良好的稳定性。海思科fast-follow迎BD大单 AZD7986化合物结构在2015年07月30日公布的专利WO2015110826A1中公开。海思科是AZD7986的国内fast-follow者，其布局的专利WO2022042591A1于2021年08月25日申请（优先权日2020年08月26日）。可知其在先申请专利日期仅仅落后Insmed在2020年6月24日美国胸科学会(ATS)虚拟会议上公布brensocatib治疗非囊性纤维化支气管扩张症(NCFBE)患者的II期WILLOW研究的阳性结果之后两个月。海思科专利公开的化合物1具有更佳的AUC0-t，且同等剂量下毒性小于INS1007，安全性更高。海思科开发的同类项目HSK31858也于2021年11月29日提交IND申请，目前该项目已进入到II期临床试验阶段。 2023年11月，海思科把HSK31858大中华区以外权益许可给Chiesi Farmaceutici，获得首付款1300万美元，外加里程碑付款和销售提成。此外，星浩澎博也有同类项目正在开发中紧随其后。案例分析海思科在DPP1抑制剂成功并获得Chiesi认可，除了研发实力，fast-follow同样尤为关键，至少海思科在该靶点已进入全球Top3的行列（除Insmed/阿斯利康合作的Brensocatib，勃林格殷格翰的BI-1291583也进入II期）。此外，DPP1作为不太热门又极具潜力的靶点开发，也为其他靶点follow提供借鉴意义。往期推荐 01 Nav1.8抑制剂fast-follow者恒瑞快速调转船头 02 吸入PDE3/4抑制剂fast-follow凑齐3家：正大天晴领跑，恒瑞延缓后被海思科追赶本文由「新药前沿」微信公众号根据公开资料整理编辑，欢迎个人转发至朋友圈。媒体或机构转载授权请在「新药前沿」微信公众号留言公众号名称，审核通过后开通白名单获取转载授权，转载请标识来源。免责声明：本文仅作信息交流之目的，非投资建议或者治疗方案推荐，「新药前沿」微信公众号不对任何主体因使用本文内容而导致的任何损失承担责任。限于作者水平和专业知识所限，如有谬误，欢迎指正！

引进/卖出临床3期专利到期临床2期

2024-07-11

·CPHI制药在线

解锁支气管扩张症，DPP1抑制剂Brensocatib三期成功，HSK31858出海

关注并星标CPHI制药在线支气管扩张症是由各种病因引起的反复发生的化脓性感染，导致中小支气管反复损伤和（或）阻塞，致使支气管壁结构破坏，引起支气管异常和持久性扩张。临床表现为慢性咳嗽、大量咳痰和（或）间断咯血、伴或不伴气促和呼吸衰竭等轻重不等的症状。支气管扩张症病因复杂，感染是重要的因素之一，其中铜绿假单胞菌（PA）是支气管扩张症气道分离的最常见病原体之一，与疾病发生及恶化显著相关。遗传性疾病如囊性纤维化和囊性纤维化跨膜传导调节因子 (CFTR)相关疾病也会影响黏液清除系统的功能，从而增加支气管扩张的风险。此外，结构性疾病、吸入性损伤、免疫缺陷等也可能导致支气管扩张症。支气管扩张症是第三大常见慢性气道疾病，且发病率呈上升趋势。当前，支气管扩张症住院药物治疗主要包括抗生素、粘液活性药物和支气管舒张剂，旨在改善气道感染、提高粘液纤毛清除能力和肺功能。近年支气管扩张症领域的可喜进展相较哮喘、慢性阻塞性肺疾病，近年来支气管扩张症领域新进展较少。2022年10月，我国NMPA批准健康元的妥布霉素吸入溶液（商品名：健可妥）用于治疗伴肺部铜绿假单胞菌感染支气管扩张症，这使健可妥成为全球首个治疗支气管扩张症的吸入式抗生素。 Insmed公司1.5亿美元从阿斯利康引进的Brensocatib也取得可喜进展。该药是一种口服、可逆的二肽基肽酶1(DPP1，一种负责激活中性粒细胞丝氨酸蛋白酶的酶)抑制剂，通过抑制DPP1减少中性粒细胞介导的疾病（如支气管扩张）中的肺损伤和炎症。 2024年5月，Insmed公司宣布Brensocatib治疗非囊性纤维化支气管扩张症（NCFBE）的3期临床试验ASPEN达到主要终点：与安慰剂相比，Brensocatib的两种剂量强度均在统计学上显著降低了肺部恶化(PEs)的年化率。具体数据为：与安慰剂相比，10mg Brensocatib治疗组在52周时实现肺恶化率降低21.1%；25mg Brensocatib组实现19.4%的降低。而且，Brensocatib两个剂量组还达到了多个次要终点，如衡量首次肺部病情加重的时间、52周内未出现病情加重的几率，具体数据请见下表。图片来源：Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis. Retrieved May 28, 2024, from https://www.prnewswire.com/news-releases/insmed-announces-positive-topline-results-from-landmark-aspen-study-of-brensocatib-in-patients-with-bronchiectasis-302156279.html 鉴于该研究结果，Insmed公司计划于今年第四季度递交新药申请。若顺利，Brensocatib有望成为首个获批治疗支气管扩张症的药物，同时也是首个获批的DPP１抑制剂。其他支气管扩张症潜在新疗法除了健可妥和Brensocatib，目前全球还有多款在研支气管扩张症新药，如XH-S004、RSS0343、HSK31858、BI1291583。其中HSK31858和BI1291583均属于DPP1抑制剂。 XH-S004为复星医药自主研发的小分子口服抑制剂，拟用于治疗非囊性纤维化支气管扩张症等，目前处于１期临床。该药通过抑制中性粒细胞的活化，从而抑制气道内中性粒细胞引起的过度炎症反应，达到治疗支气管扩张症的作用。临床前研究显示，XH-S004针对特异的靶点显示出良好的抑制活性的药效，毒理研究也展现出良好的耐受性。 RSS0343是瑞石生物开发的一款口服共价可逆小分子抑制剂，据悉其作用于参与非囊性纤维化支气管扩张症疾病进程的重要蛋白，在体内外药效学实验中显示出对靶点活性的高度抑制作用，且具有良好的选择性。2023年4月，RSS0343在国内获批临床，用于治疗非囊性纤维化支气管扩张症。 HSK31858是海思科自主研发的口服、强效和高选择性DPP1抑制剂，通过抑制DPP1进而抑制下游的与支气管扩张炎症相关的中性粒细胞丝氨酸蛋白酶（NSPs）而发挥药理作用，被开发用于治疗支气管扩张症、慢性阻塞性肺疾病、哮喘等。据海思科专利，HSK31858（推测为专利WO2022042591A1中的化合物1）在体外试验中表现出优于Brensocatib的DPP1抑制活性（非头对头研究），体内试验中也表现出更优的药代动力学特征、生物利用度和安全性。而且，1期临床试验结果显示：HSK31858具有良好的安全性和耐受性，并能剂量依赖性地抑制全血中性粒细胞弹性酶（NE）活性。已完成的HSK31858治疗非囊性纤维化支气管扩张症的2期临床试验结果显示：与安慰剂相比，HSK31858治疗12周可以显著延长非囊性纤维化支气管扩张症患者首次肺部加重所需的时间，同时降低肺部加重的频率。值得一提的是，HSK31858已受到国外药企的青睐。2023年11月，海思科将HSK31858在大中华区以外的全球开发、生产和商业化的独家权利授予Chiesi公司，据悉交易总金额4.62亿美元。 BI1291583是勃林格殷格翰开发的一款可逆性、高效、高选择性DPP1抑制剂，1期临床试验中展现出良好的安全性和耐受性。临床前研究显示：BI 1291583 会优先分布到骨髓，其中骨髓分布最多可达到血浆分布的100 倍（同一模型中，brensocatib在骨髓和血浆之间的分布几乎相等），这使BI 1291583 能够最大限度地降低皮肤事件的风险。总结新药的不断研发会改变很多疾病的治疗现状，支气管扩张症也不例外。但整体来看，支气管扩张症新药进展较慢，不过DPP1抑制剂或成为支气管扩张症治疗的新利器，Insmed公司的Brensocatib进展最快，其治疗非囊性纤维化支气管扩张症的3期临床试验已取得成功，计划递交新药申请。期待支气管扩张症领域早日迎来里程碑式进展。 END 【智药研习社抗体系列直播预告】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

临床3期临床成功临床结果临床2期

100 项与 Brensocatib 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15638

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非囊性支气管扩张	临床3期	德国	Insmed, Inc.	2020-12-01
非囊性支气管扩张	临床3期	美国	Insmed, Inc.	2020-12-01
非囊性支气管扩张	临床3期	澳大利亚	Insmed, Inc.	2020-12-01
非囊性支气管扩张	临床3期	爱尔兰	Insmed, Inc.	2020-12-01
非囊性支气管扩张	临床3期	荷兰	Insmed, Inc.	2020-12-01
非囊性支气管扩张	临床3期	马来西亚	Insmed, Inc.	2020-12-01
非囊性支气管扩张	临床3期	新西兰	Insmed, Inc.	2020-12-01
非囊性支气管扩张	临床3期	巴西	Insmed, Inc.	2020-12-01
非囊性支气管扩张	临床3期	韩国	Insmed, Inc.	2020-12-01
新型冠状病毒感染	药物发现	英国	Insmed, Inc.	2020-06-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04594369 (ASPEN, Company_Website) 人工标引	临床3期	支气管扩张	1,721	Brensocatib 10 mg	(餘廠獵積製壓願壓襯顧) = 鬱簾淵製構醖齋遞願選鹹糧構鹹齋鑰網獵網鑰 (鏇憲願鑰繭壓網蓋蓋構 ) 更多	积极	2024-05-28
				Brensocatib 25 mg	(餘廠獵積製壓願壓襯顧) = 範齋築餘築憲獵膚鬱鏇鹹糧構鹹齋鑰網獵網鑰 (鏇憲願鑰繭壓網蓋蓋構 ) 更多
Phase 1 Study of Brensocatib (ATS2024) 人工标引	临床1期	非囊性支气管扩张	28	Brensocatib (Subjects with mild renal impairment)	(餘齋壓觸築範憲築顧觸) = There were no treatment-emergent AEs, serious AEs, or death during this study. 願鹹鹽壓鬱簾壓壓選廠 (憲膚繭廠憲餘鹽廠獵願 )	积极	2024-05-22
				Brensocatib (Subjects with moderate renal impairment)
NCT04817332 (STOP-COVID19, CTgov)	临床3期	新型冠状病毒感染	406	Brensocatib (Brensocatib)	淵願積觸鹹糧衊願鹹廠(鏇糧積襯鑰製衊艱艱遞) = 淵襯膚艱願獵壓衊願壓獵蓋鹹遞醖壓齋顧窪窪 (顧範製餘鬱製願構簾鹽, 鹹蓋鏇選獵範築襯構願 ~ 獵鬱製壓艱選製襯蓋鑰) 更多	-	2023-08-22
				Placebo (Placebo)	淵願積觸鹹糧衊願鹹廠(鏇糧積襯鑰製衊艱艱遞) = 製廠鏇簾製願築鹽繭鑰獵蓋鹹遞醖壓齋顧窪窪 (顧範製餘鬱製願構簾鹽, 網鹹襯餘鬱築壓衊簾鏇 ~ 繭製鏇遞夢鏇簾壓鹹鹽) 更多
NCT03218917 (WILLOW, CTgov)	临床2期	非囊性支气管扩张	256	Brensocatib 10 mg (Brensocatib 10 mg)	醖積壓積獵簾廠廠夢淵(繭築鏇醖壓獵築遞廠壓) = 夢鹽顧窪醖鏇艱齋夢築選糧鹹觸淵鹹積顧範憲 (簾襯繭鏇窪簾鏇範鹽範, 願鏇壓糧餘壓網餘蓋願 ~ 糧糧獵壓鹽衊鏇窪鏇襯) 更多	-	2023-02-08
				Brensocatib 25 mg (Brensocatib 25 mg)	醖積壓積獵簾廠廠夢淵(繭築鏇醖壓獵築遞廠壓) = 鏇餘齋鏇網鏇糧鏇蓋壓選糧鹹觸淵鹹積顧範憲 (簾襯繭鏇窪簾鏇範鹽範, 遞顧簾窪網糧顧願構衊 ~ 選鏇築廠獵觸齋範壓廠) 更多
NCT04817332 (NEWS) 人工标引	临床3期	新型冠状病毒感染	404	Standard of Care+brensocatib	(網齋網憲艱壓繭蓋鹹遞) = Brensocatib did not improve the clinical status of patients hospitalized 蓋願鏇構蓋獵願齋餘網 (餘襯襯淵齋糧糧夢觸糧 ) 更多	不佳	2022-05-18
				Standard of Care+Placebo
NCT03218917 (WILLOW, Pubmed \| Br Dent J)	临床2期	支气管扩张	256	Placebo	(餘選製淵顧製構憲選壓) = 繭鏇憲鬱廠鹽醖醖繭選製艱鑰襯觸膚餘憲遞衊 (餘糧齋觸壓簾遞襯窪範 )	积极	2020-11-26
				Brensocatib 10 mg	(餘選製淵顧製構憲選壓) = 蓋願窪衊膚簾網鹽範選製艱鑰襯觸膚餘憲遞衊 (餘糧齋觸壓簾遞襯窪範 )